A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular Hypertension
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To estimate the frequency of patients with ocular/periorbital adverse events. To identify any
possible long-term adverse consequences of increased iris pigmentation and to follow serious
adverse events throughout the study period.